Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Medicamen Organics Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹34
Per ShareLot Size
4000 Shares
Minimum Investment
₹1,36,000
Issue Size
₹10.54 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
77.79%
Issue Type
Book Building - SME
ISIN
INE0PE401018
Medicamen Organics Limited is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. The Company markets its product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Further, the Company is also strategically focusing on establishing a direct presence in international market for an instance in fiscal 2023, it has directly exported its product in Burundi. The Company has a track record of operating B2B model which covers contract manufacturing model. Its products are marketed across India as well as African, Commonwealth of Independent States (CIS) region and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by its third-party distributor.
According to a recent EY FICCI report, there has been growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US$ 1 trillion mark in 2024. India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving into a thriving industry growing at a CAGR of 9.43% in the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most pharmaceutical manufacturing facilities that comply with the US Food and Drug Administration (USFDA) and has 500 API producers that makeup around 8% of the worldwide API market. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with the potential to steer industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the "pharmacy of the world" due to the low cost and high quality of its medicines.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offer of upto 31,00,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Medicamen Organics Limited (the "Company" or "Medicamen" or "Issuer") at an issue price of Rs. 34 per equity share (including a share premium of Rs. 24 per equity share) for cash, aggregating up to Rs. 10.54 crores ("Public Issue") out of which 1,72,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 34 per equity share for cash, aggregating Rs. 0.58 crores will be reserved for subscription by the market maker to the issue (the "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of upto 29,28,000 equity shares of face value of Rs. 10/- each at an issue price of Rs. 34 per equity share for cash, aggregating up to Rs. 9.96 crores is hereinafter referred to as the "Net Issue". The public issue and net issue will constitute 26.49 % and 25.02 % respectively of the post-issue paid-up equity share capital of the company.
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Medicamen Organics Limited was incorporated on March 15, 1995 as `Panchdeep Pharmaceuticals Limited', a public limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated March 15, 1995 issued by the Registrar of Companies, National Capital Territory (NCT) of Delhi and Haryana. Subsequently, pursuant to a resolution passed by the Board of Directors in their meeting held on July 31, 1995 and by the Shareholders in their EGM held on October 14, 1995, the name of the Company was changed to `Medicamen Organics Limited' and a fresh certificate of incorporation dated November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi.
Wholesaler and Retailer
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.